JANX
Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.24
+2.22%Margins
Gross margin
68.9%
EBITDA margin
-317.1%
EBIT margin
-450.3%
Net margin
-321.8%
FCF margin
-171.1%
-11.1%
Return on equity
-10.2%
Return on assets
-15.1%
Return on invested capital
0.03x
Asset turnover
-$53.6M
Cash from operations
$16
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026